08:00 , Jan 2, 2012 |  BC Week In Review  |  Clinical News

GSK2586881: Phase IIa started

GlaxoSmithKline began a U.S. and Canadian Phase IIa trial to evaluate GSK2586881 in ALS patients. GSK has exclusive, worldwide rights to develop and commercialize the compound from Apeiron (see BioCentury, Feb. 8, 2010). Apeiron Biologics...
08:00 , Feb 28, 2011 |  BioCentury  |  Product Development

Two for one in neuroblastoma

By activating multiple elements of the host's immune system, Apeiron Biologics AG believes its mAb fused to IL-2 will provide a one-two punch to neuroblastoma cells, without the toxic side effects of systemic IL-2 treatment. The...
07:00 , Sep 2, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Angiotensin I converting enzyme 2 (ACE2) In vitro studies suggest that increasing ACE2 levels could...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Company News

Apeiron Biologics, GlaxoSmithKline deal

Apeiron granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize APN01. The recombinant human angiotensin-converting enzyme 2 (ACE2) is in Phase I testing to treat acute respiratory distress syndrome (ARDS). Apeiron will receive...
00:45 , Feb 4, 2010 |  BC Extra  |  Company News

GSK in-licenses Apeiron's APN01

Apeiron Biologics AG (Vienna, Austria) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exclusive, worldwide rights to APN01. The recombinant human angiotensin-converting enzyme 2 (ACE2) is in Phase I testing to treat acute respiratory distress syndrome. Apeiron will...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

GL1001: Phase I data

Data from a 14-day, double-blind, placebo-controlled, ascending-dose, U.S. Phase I trial in 32 healthy volunteers showed that multiple doses up to 1,800 mg oral GL1001 were well tolerated with no serious adverse events. Ore Pharmaceuticals...
07:00 , Oct 6, 2008 |  BC Week In Review  |  Clinical News

GL1001: Phase I started

Ore began a double-blind, placebo-controlled, multiple ascending-dose, U.S. Phase I trial to evaluate oral GL1001 in up to 30 healthy volunteers. Ore Pharmaceuticals Inc. (NASDAQ:ORXE), Gaithersburg, Md.   Product: GL1001   Business: Autoimmune   Molecular target: ...
07:00 , Jul 7, 2008 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date 1Q08 oper loss 4/2/08 Genitope (NASDAQ:GTOP) 89% to ~20 $12.4 0.06 ...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Company News

Ore Pharmaceuticals Inc. autoimmune, gastrointestinal news

Ore restructured and reduced headcount by 49 (69%) to 22 to focus on clinical development and commercialization. The cuts will come from drug discovery and administrative departments. The company will seek development and commercialization partners...
07:00 , May 5, 2008 |  BC Week In Review  |  Clinical News

GL1001: Phase I start

Next half, Ore will begin a U.S. Phase I trial of oral GL1001. Ore Pharmaceuticals Inc. (NASDAQ:ORXE), Gaithersburg, Md.   Product: GL1001   Business: Gastrointestinal   Molecular target: Angiotensin-converting enzyme (ACE)   Description: Small molecule inhibitor of...